Cresset Asset Management LLC Sells 765 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Cresset Asset Management LLC cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 8.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,040 shares of the medical equipment provider's stock after selling 765 shares during the period. Cresset Asset Management LLC's holdings in Intuitive Surgical were worth $3,982,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Castleark Management LLC raised its stake in shares of Intuitive Surgical by 3.4% during the fourth quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after purchasing an additional 2,990 shares during the period. Arlington Trust Co LLC increased its stake in Intuitive Surgical by 34.5% during the first quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after purchasing an additional 191 shares during the last quarter. Aveo Capital Partners LLC increased its stake in Intuitive Surgical by 37.4% during the first quarter. Aveo Capital Partners LLC now owns 727 shares of the medical equipment provider's stock valued at $390,000 after purchasing an additional 198 shares during the last quarter. Aaron Wealth Advisors LLC grew its position in shares of Intuitive Surgical by 3.2% during the first quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock worth $1,243,000 after acquiring an additional 78 shares during the last quarter. Finally, Longbow Finance SA grew its position in shares of Intuitive Surgical by 132.0% during the first quarter. Longbow Finance SA now owns 19,699 shares of the medical equipment provider's stock worth $9,756,000 after acquiring an additional 11,209 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president directly owned 353 shares of the company's stock, valued at approximately $173,845.44. This represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary S. Guthart sold 2,800 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $495.24, for a total value of $1,386,672.00. Following the completion of the sale, the insider directly owned 18,520 shares of the company's stock, valued at $9,171,844.80. This represents a 13.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,839 shares of company stock valued at $7,896,972. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 1.3%

Intuitive Surgical stock traded up $6.28 during trading hours on Friday, reaching $476.16. 2,023,902 shares of the company were exchanged, compared to its average volume of 1,973,062. The firm has a market cap of $170.69 billion, a price-to-earnings ratio of 66.41, a PEG ratio of 4.92 and a beta of 1.59. The stock has a 50-day moving average of $504.42 and a 200 day moving average of $522.06. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company's revenue was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.78 earnings per share. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Zacks Research downgraded Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their target price for the company from $515.00 to $440.00 in a report on Monday, June 9th. Finally, UBS Group increased their price objective on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Intuitive Surgical has an average rating of "Moderate Buy" and an average target price of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.